Fulcrum Therapeutics announced the discontinuation of its sickle cell disease drug, pociredir, after the FDA expressed serious safety concerns linked to similar drugs causing high malignancy risks. This led to a 51% drop in the company's stock price, from $6.42 to $3.14 per share. The FDA's decision effectively blocks any further clinical development of pociredir, impacting Fulcrum's future prospects. Investors who suffered losses are being invited to join a securities investigation by Kaplan Fox & Kilsheimer LLP.
LCI Industries improved its profitability with an 8% rise in adjusted operating profit and a 110 basis point increase in operating margin, despite a 4% decline in net sales and weaker demand in the outdoor recreation market. Sales to OEMs fell 10%, a...
Micron Technology reported a strong third quarter with revenue rising 74% to $41.46 billion and an EPS of $25.11, driven by robust demand for its high-bandwidth memory chips used in AI servers. UBS maintains a Buy rating on the stock, citing strategi...
Powerfleet reported Q1 fiscal 2027 revenue of $110.8 million, missing analyst expectations of about $115.54 million, though revenue grew 6.4% year over year. The company posted an adjusted loss per share of -$0.01, beating the expected -$0.02, and sh...
GameSquare Holdings, Inc. is set to release its Q2 2026 earnings, with analysts expecting a loss of $0.03 per share and $17.15 million in revenue. The company faces financial challenges, including a negative P/E ratio and a current ratio below 1, ind...
Sandisk has received approval to buy back $15.5 billion worth of its own shares, representing 8.6% of the company's total stock. This move signals confidence in the company's value and can potentially increase shareholder returns by reducing the numb...
